Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis

Blood

Volumn 91, Issue 8, 1998, Pages 2875-2885

  Plumas, Joël ^a,b   Jacob, Marie Christine ^a   Chaperot, Laurence ^a   Molens, Jean Paul ^a   Sotto, Jean Jacques ^a   Bensa, Jean Claude ^a  

^a Immunology Department   (France)

^b Laboratoire d'Immunologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ANIMAL CELL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032523201     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v91.8.2875.2875_2875_2885     Document Type: Article

References (54)

1. Nagata S, Golstein P: The Fas death factor. Science 267:1449, 1995
2. Gruss HJ, Dower SK: Tumor necrosis factor ligand superfamily: Involvement in the pathology of malignant lymphomas. Blood 85:3378, 1995
3. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169, 1993
4. Trauth BC, Klas C, Peters AMJ, Matzku S, Möller P, Falk W, Debatin KM, Krammer PH: Monoclonal antibody mediated tumor regression by induction of apoptosis. Science 245:301, 1989
5. Yonehara S, Ishii A, Yonehara M: A cell killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169:1747, 1989
6. Ju ST, Panka DJ, Cui H, Ettinger R, El Khatib M, Sherr DH, Stanger BZ, Marshak-Rothstein A: Fas (CD95)/FasL interactions required for programmed cell death after T cell activation. Nature 373:444, 1995
7. Alderson MR, Tough TW, Davis Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F, Lynch DH: Fas ligand mediates activation induced cell death in human T lymphocytes. J Exp Med 181:71, 1995
8. Lowin B, Hahne M, Mattmann C, Tschopp J: Cytolytic T cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370:650, 1994
9. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perforin pathways as major mechanisms of T cell mediated cytotoxicity. Science 265:528, 1994
10. Rieux Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, De Villartay JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268: 1347, 1995
11. Fischer GH, Rosenberg FJ, Straus SE, Dale JK, Middelton LA, Lin AY, Strober W, Lenardo MJ, Puck JM: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81:935, 1995
12. Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC: Expansion or elimination of B cells in vivo: Dual roles for CD40 and Fas (CD95) ligands modulated by the B cell antigen receptor. Cell 87:319, 1996
13. Durie FH, Foy TM, Masters SR, Laman JD, Noelle RJ: The role of CD40 in the regulation of humoral and cell mediated immunity. Immunol Today 15:406, 1994
14. Banchereau J, Bazan F, Blanchard D, Briere F, Galizzi JP, Van Kooten C, Liu YJ, Rousset F, Saeland S: The CD40 antigen and its ligand. Annu Rev Immunol 12:881, 1994
15. Garrone P, Neidhardt EM, Garcia E, Galibert L, Vankooten C, Banchereau J: Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med 182:1265, 1995
16. Lagresle C, Bella C, Daniel PT, Krammer PH, Defrance T: Regulation of germinal center B cell differentiation. J Immunol 154:5746, 1995
17. Schattner EJ, Elkon KB, Yoo DH, Tumang J, Krammer PH, Crow MK, Friedman SM: CD40 ligation induces APO-1/Fas expression on human B lymphocytes and facilitates apoptosis through the APO-1/Fas pathway. J Exp Med 182:1557, 1995
18. Rothstein TL, Wang JKM, Panka DJ, Foote LC, Wang Z, Stanger B, Cui H, Ju ST, Marshak-Rothstein A: Protection against Fas-dependent Th1-mediated apoptosis by antigen receptor engagement in B cells. Nature 374:163, 1995
19. Lagresle C, Mondiere P, Bella C, Krammer PH, Defrance T: Concurrent engagement of CD40 and the antigen receptor protects naive and memory human B cells from APO-1/Fas mediated apoptosis. J Exp Med 183:1377, 1996
20. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, Dewolfpeeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Mullerhermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 84:1361, 1994
21. Friedman DF, Cho EA, Goldman J, Carmack CE, Besa EC, Hardy RR, Silberstein LE: The role of clonal selection in the pathogenesis of an autoreactive human B cell lymphoma. J Exp Med 174:525, 1991
22. Zelenetz AD, Chen TT, Levy R: Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection. J Exp Med 176:1137, 1992
23. Plumas J, Chaperot L, Jacob MC, Giroux C, Mollens JP, Sotto JJ, Bensa JC: Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: An important role of costimulatory molecules CD80 (B7-1) and CD86 (B7-2) in the stimulating function of tumor cells. Eur J Immunol 25:3332, 1995
24. Johnson PWM, Watt SM, Betts DR, Davies D, Jordan S, Norton AJ, Lister TA: Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/Stromal cell system. Blood 82:1848, 1993
25. Möller P, Henne C, Leithäuser F, Eichelmann A, Schmidt A, Brüderlein S, Dhein J, Krammer PH: Coregulation of the APO-1 antigen with intercellular adhesion molecule-1 (CD54) in tonsillar B cells and coordinate expression in follicular center B cells and in follicle center and mediastinal B cell lymphomas. Blood 81:2067, 1993
26. Kondo E, Yoshino T, Yamadori I, Matsuo Y, Kawasaki N, Minowada J, Akagi T: Expression of Bcl-2 protein and Fas antigen in non-Hodgkin's lymphomas. Am J Pathol 145:330, 1994
27. Xerri L, Carbuccia N, Parc P, Hassoun J, Birg F: Frequent expression of Fas/APO-1 in Hodgkin's disease and anaplastic large cell lymphomas. Histopathology 27:235, 1995
28. Falk MH, Trauth BC, Debatin KM, Klas C, Gregory CD, Rickinson AB, Calender A, Lenoir GM, Ellwart JW, Krammer PH, Bornkamm GW: Expression of the APO-1 antigen in Burkitt's lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype. Blood 79:3300, 1992
29. + T cell induction of Fas mediated apoptosis in Burkitt's lymphoma B cells. Blood 88:1375, 1996
30. Mapara MY, Bargou R, Zugck C, Döhner H, Ustaoglu F, Jonker RR, Krammer PH, Dörken B: APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: Correlation with Bcl-2 oncogene expression. Eur J Immunol 23:702, 1993
31. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184:39, 1995
32. Koopman G, Reutelingsperger CPM, Kuijten GAM, Keehnen RMJ, Pals ST, Van Oers MHJ: Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84:1415, 1994
33. Vignaux F, Golstein P: Fas based lymphocyte mediated cytotoxicity against syngeneic activated lymphocytes: A regulatory pathway? Eur J Immunol 24:923, 1994
34. Tsujimoto Y, Bashir MM, Givol I, Cossman J, Jaffe E, Croce CM: DNA rearrangements in human follicular lymphoma can involve the 5' or the 3' region of the Bcl-2 gene. Proc Natl Acad Sci USA 84:1329, 1987
35. Offit K, Coco FL, Louie DC, Parsa NZ, Leung D, Portlock C, Ye BH, Lista F, Filippa DA, Rosenbaum A, Ladanyi M, Jhanwar S, Dalla Favera R, Chaganti RSK: Rearrangement of the Bcl-6 gene as a prognostic marker in diffuse large cell lymphoma. N Engl J Med 331:74, 1994
36. De Boer CJ, Schuuring E, Dreef E, Peters G, Bartek J, Kluin PM, Van Krieken HJM: Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood 86:2715, 1995
37. Dalla Favera R, Bregni M, Erikson J: Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 79:7824, 1982
38. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R: p53 mutations in human lymphoid malignancies: Association with Burkitt's lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413, 1991
39. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, Raffeld M: p53 mutation is associated with progression in follicular lymphomas. Blood 82:1994, 1993
40. McDonnell TJ, Korsmeyer SJ: Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14,18). Nature 349:254, 1991
41. + T cell clones. J Immunol 144:2250, 1990
42. Foote LC, Howard RG, Marshak-Rothstein A, Rothstein TL: IL-4 induces Fas resistance in B cells. J Immunol 157:2749, 1996
43. Yang E, Korsmeyer SJ: Molecular thanatopsis: A discourse on the Bcl-2 family and cell death. Blood 88:386, 1996
44. Itoh N, Tsujimoto Y, Nagata S: Effect of Bcl-2 on Fas antigen mediated cell death. J Immunol 151:621, 1993
45. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC: Cloning and functional analysis of BAG-1: A novel Bcl-2 binding protein with anti cell death activity. Cell 80:279, 1995
46. Xerri L, Parc P, Brousset P, Schlaifer D, Hassoun J, Reed JC, Krajewski S: Predominant expression of the long isoform of Bcl-X (Bcl-xL) in human lymphomas. Br J Haematol 92:900, 1996
47. Wang Z, Karras JG, Howard RG, Rothstein TL: Induction of Bcl-x by CD40 engagement rescues sIg induced apoptosis in murine B cells. J Immunol 155:3722, 1995
48. Tuscano JM, Druey KM, Riva A, Pena J, Thompson CB, Kehrl JH: Bcl-x rather than Bcl-2 mediates CD40 dependent centrocyte survival in the germinal center. Blood 88:1359, 1996
49. Cascino I, Papoff G, De Maria R, Testi R, Ruberti G: Fas/APO-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas mediated apoptosis. J Immunol 156:13, 1996
50. Xerri L, Carbuccia N, Birg F: Search for rearrangements and/or allelic loss of the Fas/APO-1 gene in 101 human lymphomas. Am J Pathol 104:424, 1995
51. Okura T, Gong L, Kamitani T, Wada T, Okura I, Wei CF, Chang HM, Yeh ETH: Protection against Fas/APO-1 and tumor necrosis factor mediated cell death by a novel protein, sentrin. J Immunol 157:4277, 1996
52. Thome M, Schneider P, Hofmann K, Fickenscher H, Meinl E, Neipel F, Mattmann C, Burns K, Bodmer JL, Schroter M, Scaffidi C, Krammer PH, Peter ME, Tschopp J: Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 386:517, 1997
53. Peng SL, Robert ME, Hayday AC, Craft J: A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J Exp Med 184:1149, 1996
54. Kudoh S, Wang Q, Hidalgo OF, Rayman P, Tubbs RR, Edinger MG, Kolenko V, Panuto J, Bukowski R, Finke JH: Responses to T cell receptor CD3 and interleukin-2 receptor stimulation are altered in T cells from B cell non Hodgkin's lymphomas. Cancer Immunol Immunother 41:175, 1995